Abiopharma

🔍 Brophy Michael Burkes (Executive)

Company: Natera, Inc. (NTRA)

Report Date: 2025-10-27

Detailed Transactions and Holdings:

• Sold 781 shares of Common Stock at $192.324 per share (Direct)
  Date: 2025-10-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 68,408.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,237 shares of Common Stock at $191.4619 per share (Direct)
  Date: 2025-10-28 | Code: S | equity_swap_involved: 0 | shares_owned_after: 67,171.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 574 shares of Common Stock at $189.8977 per share (Direct)
  Date: 2025-10-28 | Code: S | equity_swap_involved: 0 | shares_owned_after: 66,597.00 | transaction_form_type: 4 | Footnotes: F3, F4
• Sold 404 shares of Common Stock at $191.5086 per share (Direct)
  Date: 2025-10-28 | Code: S | equity_swap_involved: 0 | shares_owned_after: 66,193.00 | transaction_form_type: 4 | Footnotes: F3, F5
• Sold 200 shares of Common Stock at $192.195 per share (Direct)
  Date: 2025-10-28 | Code: S | equity_swap_involved: 0 | shares_owned_after: 65,993.00 | transaction_form_type: 4 | Footnotes: F3, F6
• Sold 300 shares of Common Stock at $188.3733 per share (Direct)
  Date: 2025-10-29 | Code: S | equity_swap_involved: 0 | shares_owned_after: 65,693.00 | transaction_form_type: 4 | Footnotes: F3, F7
• Sold 400 shares of Common Stock at $189.9085 per share (Direct)
  Date: 2025-10-29 | Code: S | equity_swap_involved: 0 | shares_owned_after: 65,293.00 | transaction_form_type: 4 | Footnotes: F3, F8
• Sold 667 shares of Common Stock at $190.9913 per share (Direct)
  Date: 2025-10-29 | Code: S | equity_swap_involved: 0 | shares_owned_after: 64,626.00 | transaction_form_type: 4 | Footnotes: F3, F9
• Sold 500 shares of Common Stock at $192.116 per share (Direct)
  Date: 2025-10-29 | Code: S | equity_swap_involved: 0 | shares_owned_after: 64,126.00 | transaction_form_type: 4 | Footnotes: F3, F10

Footnotes:

• F1: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 26, 2024.
• F2: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 27, 2023.
• F3: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024.
• F4: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $189.49 to 190.26 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F5: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $190.88 to $191.80 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F6: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $191.93 to $192.46 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F7: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $188.06 to $189.00 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F8: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $189.24 to $190.05 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F9: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $190.42 to $191.41 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F10: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $191.98 to $192.29 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.